Skip to main content

Table 1 Sociodemographic and clinical parameters of the patient cohort analysed

From: The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry

Patient characteristics n (%) / mean (SD)
n = 424
Female 98 (23.1%)
Age in years 68.7 (9.1)
Age at first symptom onset in years 64.9 (10.3)
Age at diagnosis in years 66.8 (9.7)
Duration since first symptoms in years 3.7 (4.1)
Disease duration in months 2.0 (2.7)
  < 3 months 124 (29.5%)
 3 to < 6 months 39 (9.3%)
 More than 6 months 258 (61.3%)
Smoking status
 Never 161 (38.0%)
 Former stopped 256 (60.4%)
 Current 7 (1.7%)
Number of comorbidities
 None 95 (22.4%)
 1 124 (29.3%)
 2 107 (25.2%)
 3 63 (14.9%)
 4+ 35 (8.3%)
NHYA
 I 28 (14.7%)
 II 81 (42.6%)
 III 76 (40.0%)
 IV 5 (2.6%)
Six-minute walk distance (m) 287.7 (199.6)
% FEV1 68.3 (17.4)
% FVC 36.1 (15.9)
% DLCO 75.9 (19.4)
GAP index 4.7 (1.4)
 Stage I 72 (18.8%)
 Stage II 203 (53.0%)
 Stage III 108 (28.2%)
Overall physician’s judgement of clinical course of IPF
 Stable disease 166 (39.2%)
 Slow progression 123 (29.0%)
 Rapid progression 31 (7.3%)
 No judgement possible 104 (24.5%)
SGRQ 45.9 (19.7)
SGRQ symptoms 55.9 (21.0)
SGRQ activity 59.7 (23.6)
SGRQ impacts 34.8 (20.7)
UCSD-SOBQ 43.9 (28.8)
EQ-5D VAS 62.6 (18.5)
WHO-5 14.8 (5.7)
  1. Values are n (%) or mean (SD)
  2. DLCO diffusing capacity of the lung for carbon monoxide, EQ-5D VAS EuroQol five-dimensional questionnaire, recorded as a visual analog scale, FEV1 Forced expiratory volume in 1 s, FVC forced vital capacity, GAP index Gender, Age, Physiology index, IPF idiopathic pulmonary fibrosis, NYHA New York Heart Association functional class, SD standard deviation, SGRQ St. George’s Respiratory Questionnaire, USCD-SOBQ University of California San Diego Shortness of Breath Questionnaire, WHO-5 World Health Organization-5 Well-Being Index